Sign In
Buy CERO
$0.0100
+0 (+0%)
At Close: Jul 31, 2026
CERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AML
08:30am, Monday, 13'th Oct 2025
Study's Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial dose pending regulatory approval
CERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose Cohort
09:15am, Monday, 22'nd Sep 2025
Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohort
Top 3 Health Care Stocks You'll Regret Missing In Q3
09:12am, Tuesday, 09'th Sep 2025
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Additional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering the compound and its underlying technology
CERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid Leukemia
08:45am, Monday, 08'th Sep 2025
Study investigator of Phase 1 trial presented poster at Society of Hematologic Oncology 13th annual conference highlighting original study protocol
CERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)
08:00am, Friday, 05'th Sep 2025
Regulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company's lead cancer immunotherapy program
CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236
08:10am, Thursday, 31'st Jul 2025
Second patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results
SAN DIEGO--(BUSINESS WIRE)-- #invivoscribe--Invivoscribe Inc., a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to support CERo Therapeutics Holdings, I
SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an immunotherapy company developing the next generati
SOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advanc
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
09:10am, Wednesday, 11'th Jun 2025
SOUTH SAN FRANSCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advanc
CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing
08:15am, Friday, 06'th Jun 2025
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation
Results in 18 Issued Patents and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings,
CERO Chief Medical Officer to discuss trial protocol in poster at the American Society for Clinical Oncology Conference The first patient has been dosed and is advancing through protocol-defined evalu
CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)
08:15am, Thursday, 08'th May 2025
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance
